LONDON (Alliance News) - Summit Therapeutics PLC Wednesday said the US Food and Drug Administration has granted fast track designation for its antibiotic for treating C. difficile infection.
The biopharmaceutical company, which aims to advance therapies for Duchenne muscular dystrophy and C. difficile infection, said that SMT19969, the antibiotic, is under evaluation in a second phase proof of concept trial in patients in North America.
"Fast Track designation recognises the serious healthcare threat posed by C. difficile due to a high rate of disease recurrence, the key clinical issue in treating CDI, and underscores the importance of developing a candidate like SMT19969, which has significant potential to address both the initial infection and recurrence," Chief Executive Glyn Edwards said in a statement.
Summit Therapeutics shares were up 1.9% at 136.00 pence on Wednesday.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2015 Alliance News Limited. All Rights Reserved.
